Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 52,87 € (+180,18 %). La mediana es de 58,80 € (+211,61 %).
| Comprar |
32 |
| Mantener |
6 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Uniqure rises after William Blair 'outperform' and progress on AMT-130
Uniqure shares gained about 2.4% in premarket trading after William Blair initiated coverage with an “Outperform” rating. Analysts are broadly optimistic (11 buy, 1 hold), and agreement with the FDA on an accelerated approval pathway for AMT-130 has boosted investor sentiment. Uniqure also benefited from a solid cash position and an amended credit facility with Hercules Capital; the recent roughly 175% rally from the 52-week low is seen as company-specific. » Más en de.investing.com
uniQure receives FDA confirmation for accelerated BLA pathway for AMT-130 and reports sales increase
uniQure said the FDA confirmed in writing after a Type B meeting that a BLA filing for Huntington’s therapy AMT-130 is appropriate under an accelerated pathway based on existing clinical data. The company beat revenue consensus in Q2 with $5.84m, but reported a higher net loss per share due to increased selling, general and administrative expenses. uniQure plans to file regulatory applications in the US and the UK in Q3 2026, strengthened its balance sheet with a $259m capital raise and extended its cash runway to 2030. The announcements pushed the stock about 6.3% higher in premarket trading. » Más en de.investing.com
UniQure beats revenue estimate and secures $259 million financing through 2030
UniQure reported Q2 revenue of $5.80 million, exceeding the consensus expectation of $5.47 million, while net loss widened due to higher selling, general and administrative and non‑operating expenses. The revenue increase was driven by higher license income; rising personnel and contractor costs reflect preparations for potential product launches. Through a follow‑on placement, UniQure raised $259 million and says this secures liquidity through 2030; regulatory filings for AMT‑130 are planned for Q3 2026 and topline four‑year data are expected in September 2026. » Más en de.investing.com
uniQure presents mixed Phase I/IIa data on epilepsy gene therapy AMT‑260
In the low‑dose cohort (1x10^12 gc/mL) of the Phase I/IIa study, three of six patients showed a 79–100% reduction in disabling seizures in months 4–6; the other three patients had changes of −33% to +36% versus baseline. No serious adverse events have been reported to date; adverse events were mild to moderate, headaches were most common, and no immunosuppression was required. Recruitment of a higher‑dose cohort (3x10^12 gc/mL) is ongoing, with completion expected mid‑2026 and updated study data planned for H1 2027. The study announcement drove the share price up 67.9% to 46.29 USD and lifted market capitalization to 2.92 billion USD; an analysis by InvestingPro currently rates the stock as overvalued. » Más en de.investing.com
UniQure to seek FDA approval for Huntington's gene therapy after agency reverses stance
UniQure plans to submit an FDA application in Q3 for its experimental gene therapy for Huntington's disease after a recent meeting indicated a three-year analysis from a Phase 1/2 study could support accelerated approval. The FDA previously questioned the sufficiency of UniQure's data and had asked for a placebo-controlled trial, but now agrees the company can use external control data and wants to align on a post-approval confirmatory study comparing the treatment to standard of care. UniQure expects to finalize the confirmatory trial design before submitting its application. » Más en cnbc.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 4,59 M | 45,46 % |
| Beneficio bruto | 4,38 M | 55,58 % |
| Beneficio neto | -54,05 M | 21,24 % |
| EBITDA | -35,77 M | 18,57 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1297,98 M € |
Número de acciones | 70,14 M |
Máximo/mínimo de 52 semanas | 47,15 € - 7,96 € |
| Dividendos | No |
Beta | 0,94 |
Ratio P/E | -5,73 |
Ratio PEG | -0,40 |
Ratio P/B | 4,82 |
Ratio P/S | 70,60 |
Perfil de la empresa
uniQure N.V., una empresa de terapia génica, se dedica al desarrollo de tratamientos para pacientes que sufren enfermedades genéticas y otras enfermedades devastadoras. Su programa principal es Etranacogene dezaparvovec (AMT-061), que se encuentra en el ensayo pivotal de Fase III HOPE-B para el tratamiento de la hemofilia B. La compañía también desarrolla AMT-130, una terapia génica que se encuentra en un estudio clínico de Fase I/II para el tratamiento de la enfermedad de Huntington; AMT-060, que se encuentra en un ensayo clínico de Fase I/II para el tratamiento de la hemofilia B; AMT-210, un candidato a producto para el tratamiento de la enfermedad de Parkinson; AMT-260 para la epilepsia del lóbulo temporal; AMT-240, un candidato a producto preclínico para el tratamiento de la enfermedad de Alzheimer autosómica dominante; y AMT-161 para el tratamiento de la esclerosis lateral amiotrófica. uniQure N.V. se fundó en 1998 y tiene su sede en Ámsterdam, Países Bajos.
| Nombre | uniQure |
| CEO | Matthew C. Kapusta |
| Sede | Amsterdam,
nh Países Bajos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 05/02/2014 |
| Empleados | 221 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | QURE |
London Stock Exchange | 0EE0.L |
Frankfurt | UQ1.F |
London | 0EE0.L |
SIX | UQ1.SW |